Ophthalmology Times

QA102 data suggest signal in intermediate dry AMD, but insignificant drusen volume change

According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...
The Manila Times

MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in ...

MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from its Phase II ...
Nasdaq

Cognition Therapeutics Reports Promising Preclinical Data for Zervimesine in Protecting RPE Cells from Dry AMD at ARVO 2025

Cognition Therapeutics, Inc. presented promising preclinical data at the ARVO conference, highlighting the potential of their drug candidate zervimesine (CT1812) to protect retinal pigment epithelial ...
Business Wire

Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)

“For more than 25 years, Alcon has been a leader in vitreoretinal surgery, and we are excited to expand our offerings into the clinic, to help millions of people living with dry AMD gain vision,” said ...
Healio

Patients with geographic atrophy require careful screening, opportunity for treatment

Please provide your email address to receive an email when new articles are posted on . Click here to read the Cover Story “Specialists navigate changing, challenging landscape of geographic atrophy ...

MingMed Biotechnology Co., Ltd: MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at ...

MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas ...